Latest Breaking News On - Adding navtemadlin to ruxolitinib - Page 1 : comparemela.com

John O. Mascarenhas, MD, discusses the design and rationale of the KRT-232-109 trial, key findings from the trial, and potential future directions of the study.

New yorkUnited statesJohno mascarenhasEuropean hematology associationIcahn school of medicine at mount sinaiTisch cancer instituteHematology associationIcahn schoolMount sinaiBlood cancersMyeloid disordersPatients with primary or secondary tp53 wild type myelofibrosis who hada suboptimal response to ruxolitinibKrt 232 109 studyAdding navtemadlin to ruxolitinibTisch cancer institute